Heat Biologics Inc. (NASDAQ:HTBX) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Tuesday.

According to Zacks, “Heat Biologics, Inc. is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of various cellular therapeutic vaccines for a range of cancers and infectious diseases. The Company’s products under development include HS-110 for the treatment of non-small cell lung cancer, HS-410 for the bladder cancer treatment, HS-310 to treat ovarian cancer and HS-510 for treating triple negative breast cancer. Heat Biologics, Inc. is based in Chapel Hill, North Carolina. “

Several other equities research analysts have also recently issued reports on HTBX. Roth Capital restated a “buy” rating and issued a $2.75 target price on shares of Heat Biologics in a report on Thursday, September 15th. Noble Financial restated a “buy” rating and issued a $8.00 target price on shares of Heat Biologics in a report on Wednesday, August 17th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $6.38.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/18/heat-biologics-inc-htbx-lowered-to-hold-at-zacks-investment-research.html

Heat Biologics (NASDAQ:HTBX) traded down 0.85% on Tuesday, hitting $1.17. 283,586 shares of the stock traded hands. Heat Biologics has a 52-week low of $0.40 and a 52-week high of $4.98. The stock’s market cap is $22.80 million. The company’s 50 day moving average price is $1.34 and its 200-day moving average price is $0.95.

Heat Biologics (NASDAQ:HTBX) last posted its quarterly earnings results on Monday, August 15th. The biopharmaceutical company reported ($0.17) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.27) by $0.10. On average, analysts forecast that Heat Biologics will post ($0.76) earnings per share for the current fiscal year.

An institutional investor recently raised its position in Heat Biologics stock. Sabby Management LLC raised its stake in Heat Biologics Inc. (NASDAQ:HTBX) by 4,005.4% during the first quarter, according to its most recent 13F filing with the SEC. The fund owned 902,007 shares of the biopharmaceutical company’s stock after buying an additional 880,036 shares during the period. Sabby Management LLC owned 10.71% of Heat Biologics worth $626,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 8.62% of the company’s stock.

Heat Biologics Company Profile

Heat Biologics, Inc is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT).

5 Day Chart for NASDAQ:HTBX

Get a free copy of the Zacks research report on Heat Biologics (HTBX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Heat Biologics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.